Cempra Inc. (NASDAQ:CEMP) rose 4% during trading on Wednesday . The company traded as high as $17.96 and last traded at $17.61, with a volume of 311,814 shares trading hands. The stock had previously closed at $16.93.

CEMP has been the subject of a number of research reports. Cowen and Company reaffirmed a “buy” rating on shares of Cempra in a report on Friday, June 24th. Needham & Company LLC reiterated a “buy” rating and set a $48.00 price target on shares of Cempra in a research note on Friday, June 24th. Stifel Nicolaus dropped their price target on shares of Cempra from $51.00 to $47.00 and set a “buy” rating on the stock in a research note on Friday, June 24th. Roth Capital initiated coverage on shares of Cempra in a research note on Tuesday, June 7th. They set a “buy” rating and a $37.00 price target on the stock. Finally, Jefferies Group reiterated a “buy” rating on shares of Cempra in a research note on Sunday, May 29th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $36.80.

The firm has a 50-day moving average of $17.88 and a 200 day moving average of $18.60. The company’s market cap is $869.53 million.

Cempra (NASDAQ:CEMP) last posted its quarterly earnings results on Monday, May 2nd. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.02. The business earned $2.70 million during the quarter, compared to the consensus estimate of $3.94 million. During the same quarter in the previous year, the business posted ($0.41) earnings per share. The company’s quarterly revenue was down 80.7% compared to the same quarter last year. Equities research analysts anticipate that Cempra Inc. will post ($2.54) EPS for the current fiscal year.

Other hedge funds and institutional investors have bought and sold shares of the company. ProShare Advisors LLC increased its position in Cempra by 9.6% in the fourth quarter. ProShare Advisors LLC now owns 39,993 shares of the company’s stock worth $1,245,000 after buying an additional 3,490 shares during the last quarter. Gabelli Funds LLC increased its position in Cempra by 19.7% in the fourth quarter. Gabelli Funds LLC now owns 93,509 shares of the company’s stock worth $2,911,000 after buying an additional 15,409 shares during the last quarter. Sei Investments Co. increased its position in Cempra by 717.8% in the fourth quarter. Sei Investments Co. now owns 110,192 shares of the company’s stock worth $3,431,000 after buying an additional 96,718 shares during the last quarter. California Public Employees Retirement System increased its position in Cempra by 427.9% in the fourth quarter. California Public Employees Retirement System now owns 117,200 shares of the company’s stock worth $3,648,000 after buying an additional 95,000 shares during the last quarter. Finally, South Dakota Investment Council increased its position in Cempra by 7.3% in the fourth quarter. South Dakota Investment Council now owns 140,700 shares of the company’s stock worth $4,380,000 after buying an additional 9,600 shares during the last quarter.

Cempra Inc is a clinical-stage pharmaceutical company focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company’s lead product, solithromycin, is being developed in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP, an infection of the respiratory tract.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.